Apogee Therapeutics, Inc. (APGE)
NASDAQ:APGE
Want to see APGE full AI Analyst Report?
APGE Stock Chart & Stats
$92.20
-$0.82(-1.65%)
At close: 4:00 PM EST
$92.20
-$0.82(-1.65%)
Day’s Range― - ―
52-Week Range$34.34 - $95.32
Previous CloseN/A
Volume109.80K
Average Volume (3M)760.09K
Market Cap
$6.19B
Enterprise Value$4.64B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$8.05M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 17, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.33
Shares Outstanding61,902,733
10 Day Avg. Volume1,026,653
30 Day Avg. Volume760,090
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.37K
Enterprise Value/Ebitda-15.61
Forecast
1Y Price Target
$118.00Price Target Upside27.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-4.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthVery low leverage and large equity/assets growth from successful capital raises give Apogee durable funding flexibility. This reduces refinancing risk, supports multi-year Phase 3 programs and commercialization planning, and lowers near-term dilution pressure while R&D executes.
Late-stage Clinical ProgressRobust Part B Phase 2 efficacy and tolerability materially de-risk the pivotal path: clear go-to mid-dose and plan to start Phase 3 H2 2026. Durable maintenance data and fewer annual doses suggest a potential differentiated commercial profile with lasting competitive advantage.
Non-dilutive Financing OptionAccess to synthetic royalty tranches plus optional senior debt provides a long-term funding alternative that preserves equity. Combined with recent equity proceeds, this structure extends runway, supports commercialization investment and offers strategic flexibility without immediate dilution.
Bears Say
Pre-revenue StatusApogee has no product sales and relies on financing, milestones, or partnerships for cash flow. Until commercialization, predictable revenue streams are absent, making financial stability contingent on successful trials, partner deals, or capital markets access over the next 2–6+ months.
High Cash BurnRapidly widening operating losses and large negative free cash flow create sustained funding needs. Even with strong liquidity today, prolonged Phase 3 timelines or setbacks would raise the likelihood of further financings or debt draw, increasing dilution or leverage over time.
Single-asset ConcentrationThe company’s value is heavily tied to one lead biologic; regulatory, competitive, or safety setbacks for zumilokibart would disproportionately impair long-term prospects. Multi-indication plans help, but reliance on a single pivotal asset raises execution risk until broader pipeline is proven.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $34.34 and its highest was $95.31 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Apogee Therapeutics, Inc.’s market cap is $6.19B.
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 78 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$1.06 earnings per share for the quarter, beating the consensus estimate of -$1.066 by $0.006.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -1.07.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 61,902,733 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$1.06 in its last earnings report, beating expectations of -$1.066. Following the earnings report the stock price went up 1.891%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$118.00 (27.98% Upside)
$118.00 (27.98% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Bullish
Bullish news 79%
Bearish news 19%
Bearish news 19%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.96%
12-Months-Change
Fundamentals
Return on Equity
-32.64%
Trailing 12-Months
Asset Growth
81.14%
Trailing 12-Months
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$118.00
▲(27.98% Upside)
Technical Analysis
Ownership Overview
5.96% Insiders
30.33% Mutual Funds
6.75% Other Institutional Investors
44.78% Public Companies and
Individual Investors